UNLIMITED TURBO SHORT - MODERNA | Market Closed - Euronext Paris 12:30:00 2024-06-26 pm EDT | ||
| 5.45 EUR | +14.50% |
|
| Current month | +29.16% | ||
| 1 month | +211.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 5.45 | +14.50% |
| 24-06-25 | 4.76 | +0.63% |
| 24-06-24 | 4.73 | -4.83% |
| 24-06-21 | 4.97 | -2.55% |
| 24-06-20 | 5.1 | -3.32% |
Real-time Euronext Paris
Last update June 26, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WE5OB | |
| ISIN | NLBNPNL2S5M1 |
| Date issued | 2024-05-22 |
| Strike | 175.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.62 € |
|---|---|
| Lowest since issue | 1.7 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Certificates
- WE5OB Certificat
